Brief: Acurx Announces First Patient Enrolled In Phase 2b Clinical Trial Of Its Lead Antibiotic For Treatment Of Clostridioides Difficile Infection
06/12/2021 14:33
Dec 6 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2B CLINICAL TRIAL OF ITS
LEAD
ANTIBIOTIC FOR TREATMENT OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)
Source text for Eikon: ID:nPn3JChdDa
Further company coverage: ACXP.O
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln